Fatty Acid Amide Hydrolase (FAAH) Inhibitor Treatment of Cannabis Use Disorder (CUD)

Completed · Phase 2 · Has a placebo group

Conditions studied: Cannabis Use Disorder

In brief

A Phase 2B, 8-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Tolerability of the Fatty Acid Amide Hydrolase (FAAH) Inhibitor PF-04457845 in Adults with DSM-5 Current Cannabis Use Disorder (CUD)

Key facts

Study ID

NCT03386487

Run by

Yale University

People needed

228

Starts

2019-01-14

Expected to finish

2022-07-25

Last updated by the study team

2024-02-14

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Ages 18-60 years, inclusive.
• Male or Female.
• Individuals with DSM-V criteria for Cannabis Use Disorder .
• Positive for urinary THC-COOH at both screening visits.
• Must express a willingness at screening to set a date within the first week of randomization to attempt to quit using cannabis.

You may not qualify if…

• Clinically significant unstable medical disorders (as determined by the site investigator).
• Laboratory tests with clinically significant abnormalities (as determined by the site investigator)
• Pregnancy by history and or laboratory confirmation (serum HCG).
• Lactation.
• Physiological dependence on another substance.

Where it is running

• Connecticut Mental Health Center — New Haven, Connecticut, United States
• Johns Hopkins University — Baltimore, Maryland, United States
• Columbia University Medical College / New York State Psychiatric Institute — New York, New York, United States
• Medical University of South Carolina — Charleston, South Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.